ADC Therapeutics
NJ - New ProvidenceBiotechnology
Focus: ADC Therapeutics is a focused oncology/hematology biotech specializing in antibody-drug conjugates (ADCs), a high-potential modality for targeted cancer therapy. The company has one commercial product (ZYNLONTA) generating $675K in Part D spending and a pipeline of 12 programs across hematologic and solid tumors.
Profile data last refreshed 2h ago · AI intelligence enriched 2w ago
Funding Stage
PRIVATE
Open Jobs
6+3 this month
Stable — net +3 jobs in 30d
3 added, 0 removed. Backfill posture.
Should You Work at ADC Therapeutics?
AI assessmentA specialized biotech bet for mission-driven scientists/oncology professionals, but revenue concentration and minimal hiring growth present career stability concerns.
Why Work Here
- Deep expertise in ADC platform—a high-growth, clinically validated modality with multiple shots on goal across 12 pipeline programs
- One approved product (ZYNLONTA) generating revenue provides company stability versus pre-revenue startups
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
$675K Part DStable
Peak
Only approved product and sole revenue source; also in Phase 3 expansion for same indication, suggesting label expansion potential.
Products & Portfolio (1)
Help build intelligence for ADC Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.